News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nitto Denko Corporation (XETRA: ND5.DE): New Anti-fibrosis Drug With Molecular Targeting DDS Completed Phase-1a Dose Escalation


4/22/2014 8:07:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OSAKA, Japan--(BUSINESS WIRE)--Nitto Denko Corporation (Nitto) (TOKYO:6988) (ISIN:JP3684000007) has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof.Yoshiro Niitsu of Sapporo Medical University. In June 2013, Nitto initiated a phase-1 clinical study in the US, and it is happy to announce that dosing in healthy volunteers has been completed. Currently, Nitto is advancing the drug to phase-1/2 clinical study in patients for the assessment of safety and efficacy.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES